Barter, Devra M

Burden of Candidemia in the United States, 2017

Tsay, S. V., Mu, Y., Williams, S., Epson, E., Nadle, J., Bamberg, W. M., Barter, D. M., Johnston, H. L., Farley, M. M., Harb, S., et al. (2020) · Clinical Infectious Diseases

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 163

The Landscape of Candidemia During the Coronavirus Disease 2019 (COVID-19) Pandemic

Seagle, E. E., Jackson, B. R., Lockhart, S. R., Georgacopoulos, O., Nunnally, N. S., Roland, J., Barter, D. M., Johnston, H. L., Czaja, C. A., Kayalioglu, H., et al. (2022) · Clinical Infectious Diseases

Antifungal resistance and susceptibilityCOVID-19 Clinical Research Studies

Cited by 141

The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection.

Linas, B. P., Barter, D. M., Morgan, J. R., Pho, M. T., Leff, J. A., Schackman, B. R., Horsburgh, C. R., Assoumou, S. A., Salomon, J. A., Weinstein, M. C., et al. (2015) · Annals of Internal Medicine

Hepatitis C virus researchHealth Systems, Economic Evaluations, Quality of Life

Cited by 101

Candida Bloodstream Infections Among Persons Who Inject Drugs — Denver Metropolitan Area, Colorado, 2017–2018

Barter, D. M., Johnston, H. L., Williams, S. R., Tsay, S. V., Vallabhaneni, S., & Bamberg, W. M. (2019) · MMWR. Morbidity and Mortality Weekly Report

Antifungal resistance and susceptibilityInfective Endocarditis Diagnosis and Management

Cited by 22

Treatment practices for adults with candidemia at 9 active surveillance sites—United States, 2017–2018.

Gold, J. A. W., Seagle, E. E., Nadle, J., Barter, D. M., Czaja, C. A., Johnston, H., Farley, M. M., Thomas, S., Harrison, L. H., Fischer, J., et al. (2021) · Clinical Infectious Diseases

Antifungal resistance and susceptibilityFungal Infections and Studies

Cited by 20